NASDAQ · COGT
Healthcare · Biotechnology
$32.00
Up+$0.63 (+1.97%)
Updated Sep 22, 2026, 10:52 PM
SID Score
4.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
COGT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning COGT.
COGT research
Company profile and research snapshot.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | Wedbush | Outperform | — |
| Sep 15, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 17, 2026 | Piper Sandler | Overweight | — |
| Aug 12, 2026 | Guggenheim | Buy | — |
| May 29, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Benzinga · Sep 17, 2026
Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 18.64% on an annualized basis producing an average annual return of 30.55%. Currently, Cogent Biosciences has a market capitalization
Benzinga · Sep 16, 2026
Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
Yahoo · Sep 15, 2026
NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set for June 29, 2027 WALTHAM, Mass. and BOULDER, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has accep
Benzinga · Sep 15, 2026
HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $55 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COGT.
